CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 129 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2023. The put-call ratio across all filers is 1.90 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,280,511 | +233144.3% | 31,316 | +140.9% | 0.01% | +150.0% |
| Q1 2024 | $549 | +32.3% | 13,000 | +32.7% | 0.00% | 0.0% |
| Q4 2023 | $415 | +86.9% | 9,800 | -3.9% | 0.00% | +100.0% |
| Q3 2023 | $222 | -31.5% | 10,200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $324 | +13.7% | 10,200 | -12.8% | 0.00% | – |
| Q1 2023 | $285 | +131.7% | 11,700 | +200.0% | 0.00% | -100.0% |
| Q4 2022 | $123 | -99.9% | 3,900 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $110,000 | +161.9% | 3,900 | +143.8% | 0.00% | – |
| Q2 2022 | $42,000 | -25.0% | 1,600 | 0.0% | 0.00% | – |
| Q1 2022 | $56,000 | +9.8% | 1,600 | 0.0% | 0.00% | – |
| Q4 2021 | $51,000 | +8.5% | 1,600 | 0.0% | 0.00% | – |
| Q3 2021 | $47,000 | -77.6% | 1,600 | -80.5% | 0.00% | -100.0% |
| Q2 2021 | $210,000 | – | 8,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |